Insulin sensitisers and prompt revascularisation offer little cost benefit Clinical study 23 January 2013 Pages: 1 - 1
Ofatumumab [Arzerra] and romidepsin [istodax] are now included in the Clinical Practice Guidelines in Oncology Media release 23 January 2013 Pages: 2 - 2
Effient [prasugrel] has received Class I recommendations for use in angioplasty, ST-elevation myocardial infarction or severe heart attack Media release 23 January 2013 Pages: 2 - 2
Based on the number of avoidable hospitalisations, it appears that the quality of primary care is better in France than in the UK Clinical study 23 January 2013 Pages: 3 - 3
Trastuzumab should be considered cost effective in France Clinical study 23 January 2013 Pages: 5 - 5
Colorectal cancer: annual surveillance carries high costs Non-clinical study 23 January 2013 Pages: 7 - 7
BRCA mutation screening cost effective for cancer prevention Non-clinical study 23 January 2013 Pages: 7 - 7
Adherence to mesalazine lowers overall UC treatment costs Clinical study 23 January 2013 Pages: 7 - 7
Bipolar disorder: screening may improve diagnoses, costs Non-clinical study 23 January 2013 Pages: 8 - 8
Endoscopic therapy outperforms surgery for oesophageal cancer Non-clinical study 23 January 2013 Pages: 8 - 8
Enhancing access to safe abortion in Mexico and Nigeria is more cost- and life-saving than switching between modalities Clinical study 23 January 2013 Pages: 9 - 9
NICE has increased its capacity for appraising new drugs and treatments, and will be able to review existing NICE appraisals more quickly News item 23 January 2013 Pages: 10 - 10
A NICE refusal to approve abatacept [Orencia] for general use in rheumatoid arthritis within the NHS has been upheld in the High Court in London News item 23 January 2013 Pages: 10 - 10
Sales of human epidermal growth factor receptor 2 (HER2)-targeting breast cancer therapies are set to grow by 3.3% per annum Media release 23 January 2013 Pages: 11 - 11
Patient flow to Humira [adalimumab] and Enbrel [etanercept] will be negatively affected by the introduction of Stelara [ustekinumab] Media release 23 January 2013 Pages: 11 - 11